Ligand Reports First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- HSBC Downgrades IBM (IBM) to Reduce, 'Stretched Valuation'
Ligand Pharma (LGND) Tops Q1 EPS by 23c; Raises Outlook
May 6, 2020 4:04 PM EDTLigand Pharma (NASDAQ: LGND) reported Q1 EPS of $0.89, $0.23 better than the analyst estimate of $0.66. Revenue for the quarter came in at $33.2 million versus the consensus estimate of $26.53 million.
Our first quarter financial results feature strong sales of Captisol to partners evaluating remdesivir in multiple... More
